<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02058940</url>
  </required_header>
  <id_info>
    <org_study_id>13-1391</org_study_id>
    <secondary_id>Astra Zeneca Pharmaceuticals</secondary_id>
    <secondary_id>Medtronic MiniMed, Inc</secondary_id>
    <nct_id>NCT02058940</nct_id>
  </id_info>
  <brief_title>Intravenous Exenatide in Patients With Acute Brain Injury</brief_title>
  <official_title>Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility of exenatide infusion for the
      treatment of high blood sugars following acute brain injury.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Critically Ill Patients With Acute Brain Injury Achieving Pre-specified Feasibility Criteria</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Feasibility is defined as the percentage of patients 1) experiencing severe hypoglycemia (&lt;40 mg/dL); 2) achieving glucose measurements within goal (110-180 mg/dL); and 3) experiencing nausea requiring discontinuation of exenatide therapy. The pre-specified criteria for determining feasibility includes the following: 1) at least 75% of patients achieving glucose measurements within goal (110-180 mg/dL) and 2) no more than 25% of patients experiencing severe hypoglycemia (&lt;40 mg/dL) or nausea requiring exenatide discontinuation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Glucose Concentration During Exenatide Infusion</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Glucose Measurements Within Goal Range</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Percentage of glucose measurements within goal range is calculated as the number of glucose measurements within goal range (110-180 mg/dL) for all patients/total number of glucose measurements collected for all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Reach Glucose Measurements Within Goal Range (110-180 mg/dL)</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Variability</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Glycemic variability is defined as the standard deviation of glucose calculated from hourly glucose measurements starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Insulin Use</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from number of insulin units administered over 48 hours starting at infusion initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Requiring Rescue Insulin Infusion Protocol</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Defined as the percentage of patients requiring an insulin infusion to control glucose concentrations during exenatide treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Hypoglycemic Episodes (&lt;80 mg/dL)</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Percentage of hypoglycemic episodes is calculated as the total number of glucose measurements &lt;80 mg/dL for all patients/total number of glucose measurements collected for all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With &gt;1 Episode of Hypoglycemia (&lt;80 mg/dL)</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Experiencing Metabolic Crisis</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Metabolic crisis is defined as cerebral microdialysate glucose concentration &lt;0.7 mmol/L in combination with lactate pyruvate ratio &gt;40. Calculated from hourly microdialysis samples starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Daily Intracranial Pressure</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly measurements starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Daily Cerebral Perfusion Pressure</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly measurements starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Hypotensive Episodes (SBP&lt;100 mmHg)</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Defined as the number of hypotensive episodes (SBP&lt;100 mmHg)for all patients/total number of blood pressure measurements collected for all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With &gt;1 Episode of Hypotensive Episode (SBP&lt;100 mmHg)</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from blood pressure measurements starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Exenatide Concentrations With Creatinine Clearance</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Spearman's correlation coefficient calculated from exenatide concentrations and urine creatinine measurements collected for all patients during the study period. A correlation coefficient is a numerical measure of some type of correlation, meaning a statistical relationship between two variables. Spearman's correlation coefficient assumes values in the range from −1 to +1, where +1 indicates the strongest possible agreement and −1 the strongest possible disagreement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exenatide Elimination Rate Constant After Discontinuation of Infusion</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exenatide Area Under the Concentration-time Curve After Discontinuation of Infusion</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Intensive Care Unit Length of Stay</measure>
    <time_frame>From enrollment to 30 days post study drug discontinuation</time_frame>
    <description>Defined as the number of days admitted to the Intensive Care Unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Hospital Length of Stay</measure>
    <time_frame>From enrollment to 30 days post study drug discontinuation</time_frame>
    <description>Defined as the number of days admitted to the hospital</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Brain Injuries</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
    <arm_group_label>Exenatide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 years

          -  Acute brain injury resulting in admission to the Neurosciences Intensive Care Unit for
             an anticipated length of stay &gt;48 hours

          -  Two Blood glucose concentrations &gt; 150 mg/dL and ≤300 mg/dL

          -  Informed consent obtained via proxy

        Exclusion Criteria:

          -  Pregnant (verified by urine or serum pregnancy test within 24 hours of initiation of
             infusion) or lactating females

          -  Type 1 diabetes mellitus

          -  History of pancreatitis or risk factors for acute pancreatitis (i.e ethanol abuse,
             gall stones)

          -  Renal insufficiency defined as creatinine clearance (CrCL) &lt; 45 mL/min

          -  Known history of gastroparesis

          -  History of surgery on stomach, esophagus or duodenum

          -  Diabetic Ketoacidosis or Hyperosmolar Hyperglycemic Nonketotic Syndrome

          -  Concurrent steroid use or planned post-operative steroid use

          -  History of organ transplantation

          -  Brain death or suspected imminent brain death within the next 72 hours

          -  Refractory intracranial hypertension defined as intracranial pressure (ICP) &gt; 25 mmHg
             for greater than 15 minutes and refractory to medical intervention

          -  Currently enrolled in another investigational drug or device protocol

          -  Insulin infusion within 3 hours of study drug administration or confirmed long acting
             insulin or sulfonylurea use prior to admission within 24 hours of study drug
             administration

          -  Known allergy to exenatide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole R. Pinelli, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina; UNC Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>February 6, 2014</study_first_submitted>
  <study_first_submitted_qc>February 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2014</study_first_posted>
  <results_first_submitted>June 1, 2018</results_first_submitted>
  <results_first_submitted_qc>July 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2018</results_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02058940/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exenatide</title>
          <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discharged from Critical Care Unit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exenatide</title>
          <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" lower_limit="58.8" upper_limit="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Admitting Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Intracerebral Hemorrhage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Ischemic Stroke</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subarachnoid Hemorrhage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subdural Hematoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glasgow Coma Scale (GCS)</title>
          <description>The Glasgow Coma Scale (GCS) aims to give a reliable and objective way of recording the conscious state of a person in response to defined stimuli. A patient is assessed against criteria of the scale, and the resulting points give a patient score between 3 and 15. Lower scores reflect a deeper state of unconsciousness.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" lower_limit="7.0" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sequential Organ Failure Assessment (SOFA)</title>
          <description>Sequential Organ Failure Assessment (SOFA) score evaluates six systems: respiratory, cardiovascular, coagulation, hepatic, renal and neurological. Each system gets a score from 0 (normal) to 4 (abnormal) and the sum of each score defines the final SOFA score, where 24 is the maximum score (high risk of mortality) and 0 is the minimum score (low risk of mortality).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hunt and Hess Scale</title>
          <description>The Hunt and Hess scale is one of the grading systems used to classify the severity of a subarachnoid hemorrhage. It gives an index of the mortality associated with the various grades. The mortality is lowest with grade 1 and highest with grade 5.</description>
          <population>Hunt and Hess Grade is only reported for patients with an admitting diagnosis of Subarachnoid Hemorrhage</population>
          <units>units on a scale</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Fisher Grade</title>
          <description>The Modified Fisher Grade classifies the appearance of subarachnoid hemorrhage on CT scan. The appearance of the hemorrhage is determined on a scale of 0 (none evident) to 4 (most severe).</description>
          <population>Modified Fisher Grade is only reported for patients with an admitting diagnosis of Subarachnoid Hemorrhage</population>
          <units>units on a scale</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intracranial Pressure</title>
          <description>Intracranial pressure (ICP) is the pressure inside the skull and thus in the brain tissue and cerebrospinal fluid (CSF). ICP is measured in millimeters of mercury (mmHg) and, at rest, is normally 7–15 mmHg.</description>
          <population>ICP is only reported in patients with Subarachnoid Hemorrhage. No patients with an admitting diagnosis of Subarachnoid Hemorrhage received ICP monitoring as part of standard of care and therefore data is not reported.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cerebral Perfusion Pressure</title>
          <description>Cerebral perfusion pressure, or CPP, is the net pressure gradient causing cerebral blood flow to the brain (brain perfusion). It must be maintained within narrow limits because too little pressure could cause brain tissue to become ischemic (having inadequate blood flow), and too much could raise intracranial pressure (ICP).</description>
          <population>CPP is only reported in patients with Subarachnoid Hemorrhage. No patients with an admitting diagnosis of Subarachnoid Hemorrhage received CPP monitoring as part of standard of care and therefore data is not reported.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Past Medical History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Diabetes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipidemia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Kidney Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Failure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (%)</title>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" lower_limit="5.5" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191.0" lower_limit="159.0" upper_limit="224.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intensive Care Unit (ICU) Day of Study Drug Administration</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Critically Ill Patients With Acute Brain Injury Achieving Pre-specified Feasibility Criteria</title>
        <description>Feasibility is defined as the percentage of patients 1) experiencing severe hypoglycemia (&lt;40 mg/dL); 2) achieving glucose measurements within goal (110-180 mg/dL); and 3) experiencing nausea requiring discontinuation of exenatide therapy. The pre-specified criteria for determining feasibility includes the following: 1) at least 75% of patients achieving glucose measurements within goal (110-180 mg/dL) and 2) no more than 25% of patients experiencing severe hypoglycemia (&lt;40 mg/dL) or nausea requiring exenatide discontinuation.</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Critically Ill Patients With Acute Brain Injury Achieving Pre-specified Feasibility Criteria</title>
          <description>Feasibility is defined as the percentage of patients 1) experiencing severe hypoglycemia (&lt;40 mg/dL); 2) achieving glucose measurements within goal (110-180 mg/dL); and 3) experiencing nausea requiring discontinuation of exenatide therapy. The pre-specified criteria for determining feasibility includes the following: 1) at least 75% of patients achieving glucose measurements within goal (110-180 mg/dL) and 2) no more than 25% of patients experiencing severe hypoglycemia (&lt;40 mg/dL) or nausea requiring exenatide discontinuation.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage Experiencing Severe Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage Achieving Glucose within Goal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage with Nausea Requiring Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Glucose Concentration During Exenatide Infusion</title>
        <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Median Glucose Concentration During Exenatide Infusion</title>
          <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.0" lower_limit="118.0" upper_limit="164.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Glucose Measurements Within Goal Range</title>
        <description>Percentage of glucose measurements within goal range is calculated as the number of glucose measurements within goal range (110-180 mg/dL) for all patients/total number of glucose measurements collected for all patients.</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Glucose Measurements Within Goal Range</title>
          <description>Percentage of glucose measurements within goal range is calculated as the number of glucose measurements within goal range (110-180 mg/dL) for all patients/total number of glucose measurements collected for all patients.</description>
          <units>percentage of measurements</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Reach Glucose Measurements Within Goal Range (110-180 mg/dL)</title>
        <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Reach Glucose Measurements Within Goal Range (110-180 mg/dL)</title>
          <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.0" lower_limit="72.5" upper_limit="270.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Variability</title>
        <description>Glycemic variability is defined as the standard deviation of glucose calculated from hourly glucose measurements starting at infusion initiation over 48 hours</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Variability</title>
          <description>Glycemic variability is defined as the standard deviation of glucose calculated from hourly glucose measurements starting at infusion initiation over 48 hours</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="15.0" upper_limit="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Insulin Use</title>
        <description>Calculated from number of insulin units administered over 48 hours starting at infusion initiation</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Median Insulin Use</title>
          <description>Calculated from number of insulin units administered over 48 hours starting at infusion initiation</description>
          <units>units/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="0.0" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Requiring Rescue Insulin Infusion Protocol</title>
        <description>Defined as the percentage of patients requiring an insulin infusion to control glucose concentrations during exenatide treatment</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Requiring Rescue Insulin Infusion Protocol</title>
          <description>Defined as the percentage of patients requiring an insulin infusion to control glucose concentrations during exenatide treatment</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Hypoglycemic Episodes (&lt;80 mg/dL)</title>
        <description>Percentage of hypoglycemic episodes is calculated as the total number of glucose measurements &lt;80 mg/dL for all patients/total number of glucose measurements collected for all patients.</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Hypoglycemic Episodes (&lt;80 mg/dL)</title>
          <description>Percentage of hypoglycemic episodes is calculated as the total number of glucose measurements &lt;80 mg/dL for all patients/total number of glucose measurements collected for all patients.</description>
          <units>percentage of measurements</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With &gt;1 Episode of Hypoglycemia (&lt;80 mg/dL)</title>
        <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With &gt;1 Episode of Hypoglycemia (&lt;80 mg/dL)</title>
          <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Experiencing Metabolic Crisis</title>
        <description>Metabolic crisis is defined as cerebral microdialysate glucose concentration &lt;0.7 mmol/L in combination with lactate pyruvate ratio &gt;40. Calculated from hourly microdialysis samples starting at infusion initiation over 48 hours</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <population>No patients received invasive intracranial multimodal monitoring as a part of their standard of care, as such, these endpoints were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Experiencing Metabolic Crisis</title>
          <description>Metabolic crisis is defined as cerebral microdialysate glucose concentration &lt;0.7 mmol/L in combination with lactate pyruvate ratio &gt;40. Calculated from hourly microdialysis samples starting at infusion initiation over 48 hours</description>
          <population>No patients received invasive intracranial multimodal monitoring as a part of their standard of care, as such, these endpoints were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Daily Intracranial Pressure</title>
        <description>Calculated from hourly measurements starting at infusion initiation over 48 hours</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <population>No patients with an admitting diagnosis of Subarachnoid Hemorrhage received ICP or CPP monitoring as part of standard of care and therefore data is not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Median Daily Intracranial Pressure</title>
          <description>Calculated from hourly measurements starting at infusion initiation over 48 hours</description>
          <population>No patients with an admitting diagnosis of Subarachnoid Hemorrhage received ICP or CPP monitoring as part of standard of care and therefore data is not reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Daily Cerebral Perfusion Pressure</title>
        <description>Calculated from hourly measurements starting at infusion initiation over 48 hours</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <population>No patients with an admitting diagnosis of Subarachnoid Hemorrhage received ICP or CPP monitoring as part of standard of care and therefore data is not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Median Daily Cerebral Perfusion Pressure</title>
          <description>Calculated from hourly measurements starting at infusion initiation over 48 hours</description>
          <population>No patients with an admitting diagnosis of Subarachnoid Hemorrhage received ICP or CPP monitoring as part of standard of care and therefore data is not reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Hypotensive Episodes (SBP&lt;100 mmHg)</title>
        <description>Defined as the number of hypotensive episodes (SBP&lt;100 mmHg)for all patients/total number of blood pressure measurements collected for all patients.</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Hypotensive Episodes (SBP&lt;100 mmHg)</title>
          <description>Defined as the number of hypotensive episodes (SBP&lt;100 mmHg)for all patients/total number of blood pressure measurements collected for all patients.</description>
          <units>percentage of measurements</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With &gt;1 Episode of Hypotensive Episode (SBP&lt;100 mmHg)</title>
        <description>Calculated from blood pressure measurements starting at infusion initiation over 48 hours</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With &gt;1 Episode of Hypotensive Episode (SBP&lt;100 mmHg)</title>
          <description>Calculated from blood pressure measurements starting at infusion initiation over 48 hours</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Exenatide Concentrations With Creatinine Clearance</title>
        <description>Spearman's correlation coefficient calculated from exenatide concentrations and urine creatinine measurements collected for all patients during the study period. A correlation coefficient is a numerical measure of some type of correlation, meaning a statistical relationship between two variables. Spearman's correlation coefficient assumes values in the range from −1 to +1, where +1 indicates the strongest possible agreement and −1 the strongest possible disagreement.</description>
        <time_frame>Over 48 hours from infusion initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Exenatide Concentrations With Creatinine Clearance</title>
          <description>Spearman's correlation coefficient calculated from exenatide concentrations and urine creatinine measurements collected for all patients during the study period. A correlation coefficient is a numerical measure of some type of correlation, meaning a statistical relationship between two variables. Spearman's correlation coefficient assumes values in the range from −1 to +1, where +1 indicates the strongest possible agreement and −1 the strongest possible disagreement.</description>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>Spearman's Correlation Coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exenatide Elimination Rate Constant After Discontinuation of Infusion</title>
        <time_frame>24 hours</time_frame>
        <population>The institutional review board requested the study team limit exenatide concentration sampling to during the infusion. Samples were not collected after discontinuation of study drug. As such, this pharmacokinetic parameter is not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Exenatide Elimination Rate Constant After Discontinuation of Infusion</title>
          <population>The institutional review board requested the study team limit exenatide concentration sampling to during the infusion. Samples were not collected after discontinuation of study drug. As such, this pharmacokinetic parameter is not reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exenatide Area Under the Concentration-time Curve After Discontinuation of Infusion</title>
        <time_frame>24 hours</time_frame>
        <population>The institutional review board requested the study team limit exenatide concentration sampling to during the infusion. Samples were not collected after discontinuation of study drug. As such, this pharmacokinetic parameter is not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Exenatide Area Under the Concentration-time Curve After Discontinuation of Infusion</title>
          <population>The institutional review board requested the study team limit exenatide concentration sampling to during the infusion. Samples were not collected after discontinuation of study drug. As such, this pharmacokinetic parameter is not reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Intensive Care Unit Length of Stay</title>
        <description>Defined as the number of days admitted to the Intensive Care Unit</description>
        <time_frame>From enrollment to 30 days post study drug discontinuation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Median Intensive Care Unit Length of Stay</title>
          <description>Defined as the number of days admitted to the Intensive Care Unit</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="7.8" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Hospital Length of Stay</title>
        <description>Defined as the number of days admitted to the hospital</description>
        <time_frame>From enrollment to 30 days post study drug discontinuation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Median Hospital Length of Stay</title>
          <description>Defined as the number of days admitted to the hospital</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="9.0" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study enrollment to 30 days post discontinuation of Exenatide, up to 1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exenatide</title>
          <description>Exenatide: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>All 3 patients completed study treatment. Cause of death due to underlying neurological injury with family deciding to place patients on comfort care.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial ended early and did not achieve targeted recruitment goals.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nicole R. Pinelli</name_or_title>
      <organization>The University of North Carolina at Chapel Hill</organization>
      <phone>919-962-1641</phone>
      <email>nickipinelli@unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

